Rigrodsky & Long, P.A. Announces Class Action Asserting Violations Of The Federal Securities Laws By Pacific Biosciences Of California, Inc.

Rigrodsky & Long, P.A. has commenced a class action asserting violations of the Federal securities laws by Pacific Biosciences of California, Inc. (“PACB” or the “Company”) (NASDAQ GS: PACB) on behalf of PACB shareholders. On April 6, 2012, the Court appointed Rigrodsky & Long, P.A. lead counsel in connection with the litigation.

If you are a PACB shareholder who purchased your stock pursuant or traceable to the Company’s Initial Public Offering on October 27, 2010 (the “IPO”) or from J.P. Morgan Securities LLC or from Deutsche Bank Securities, Inc., and would like to learn more about litigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/news/pacific-biosciences-of-california-inc-pacb-ipo.

PACB is a development stage company that develops, manufactures, and markets an integrated platform for genetic analysis. The Company engages in commercializing a platform, single molecule, real-time technology (SMRT) for the detection of biological events.

Among other things, the litigation alleges that the Company failed to disclose in connection with its IPO that, contrary to the PACB’s claim that its RS DNA sequencing system had a 99.99% accuracy rate, the RS’s raw-read accuracy rate was only 80%-84% such that would-be customers would have to sacrifice long read length to obtain increased raw-read accuracy, that countless insidious bugs in the RS system caused it to be highly unreliable and crash often, and that significant negative feedback had been received from limited production users of the system.

On August 5, 2011, J.P. Morgan issued a report cutting PACB’s rating from Overweight to Neutral, stating that due to a slower ramp-up in orders now being expected it was “lowering [its] 2012 projection from systems recognized from 170 to 90” and is now “not forecast[ing] operating profitability until after 2015.” In reaction to this news, PACB stock plunged 34% to close at $6.50 per share on August 5, 2011.

If you liked this article you might like

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Health Sector Down As Report of Industry Price Collusion Surfaces

Illumina Shares Hammered by Sales Forecast Cut